These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Exempt 2005-004313-15 A Phase I/IIa, Double-blind, Randomized, Placebo-controlled, Dose-Escalation Study of NI-0401 in Patients with Moderate to Severe Active Crohn´s Disease 2006-12-10 not-yet-due
Listed as ongoing, but also has a completion date 2007-001857-24 A Phase IIa, open-label, dose-titration, multicenter study to assess the safety and preliminary efficacy of NI-0401 in patients with acute cellular renal allograftt rejection 2008-12-03 bad-data
Not reported Terminated 2009-012988-34 A multicenter, randomized, double-blind, placebo-controlled clinical trial investigating the safety and efficacy of NI-0401 in patients with newly diagnosed Type 1 Diabetes Mellitus (T1D) 2009-10-26 due-trials
Not reported Terminated 2011-001326-26 PIANO. Primary Biliary Cirrhosis: Investigating A New Treatment Option using NI-0801, a fully human anti-CXCL10 monoclonal antibody. An open label single arm study to investigate the safety and effica... 2012-10-10 due-trials
Listed as ongoing, but also has a completion date and reported results 2012-003632-23 A Phase 2/3, Open-label, Single Arm, Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Multiple Administrations of NI-0501, an Anti-interferon Gamma (Anti-... 2019-01-04 bad-data
Listed as ongoing, but also has a completion date 2012-005753-23 A multicentre study for the long-term follow-up of HLH patients who received treatment with NI-0501, an anti-interferon gamma monoclonal antibody 2017-12-21 bad-data
Listed as ongoing, but also has a completion date 2016-004223-23 A pilot, open-label, single arm, multicenter study to evaluate safety, tolerability, pharmacokinetics and efficacy of intravenous administrations of emapalumab, an anti-interferon gamma (anti-IFNγ) mo... 2020-05-19 bad-data
Reported results 2016-005017-45 A Randomized, Placebo-Controlled, Double Blind, Multicenter Phase 2 Study to Explore Tolerability, Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Intravenous Multiple Infusions of NI-0101,... 2018-05-17 due-trials
Ongoing 2017-003114-10 An Open-label, Single Arm, Multicenter Study to Broaden Access to Emapalumab, an Anti-Interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and to Assess its Efficacy, Safety, Impact on Quality of Life, a... not-yet-due